Psychological distress reported for indolent non-Hodgkin lymphomas
Patients with indolent non-Hodgkin lymphomas (iNHL) report considerable psychological distress, according to a study published online Nov. 3 in The Oncologist.
Nov 21, 2023
0
105
Pathological Conditions, Signs and Symptoms: News and Research on Leukemia, Lymphocytic, Chronic, B-Cell
MeSH tree: C23.550.291.500.483
First in human trial of new drug raises hopes for patients with relapsed blood cancer
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James), may offer a new treatment option ...
Nov 6, 2023
0
84
Drug mechanism opens door for new anti-cancer immunotherapies
Researchers have revealed a new mechanism of targeted drug treatment used against chronic lymphocytic leukemia, through the promotion of immune cell function, that could be exploited using new anti-cancer immunotherapies.
Oct 19, 2023
0
66
As COVID infections rise, nursing homes are still waiting for vaccines
"COVID is not pretty in a nursing home," said Deb Wityk, a 70-year-old retired massage therapist who lives in one called Spurgeon Manor, in rural Iowa. She twice contracted the disease and is eager to get the newly approved ...
Sep 28, 2023
0
39
Study finds increased MDS/leukemia risks for survivors of common lymphoid neoplasms
Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been lower in more recent years, according to a study published ...
Aug 17, 2023
0
139
Immunotherapy improves remission for relapsed, refractory leukemia: Clinical trial
A single infusion of chimeric antigen receptor T-cell (CAR-T) therapy induced complete response or remission in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), ...
Jul 14, 2023
0
94
Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia
First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically ...
Jun 7, 2023
0
70
Combination therapy outperforms chemotherapy in clinical trial for patients with chronic lymphocytic leukemia
Chemotherapy has been the most effective treatment to date for young and fit patients with chronic lymphocytic leukemia (CLL). The disease is the most common form of leukemia in the Western world, causing a substantial health ...
May 10, 2023
0
95
The impact of cortactin in cancer progression
A new editorial paper titled " Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway" has been published in Oncotarget.
Apr 4, 2023
0
46
Large-scale study of nine genes in 4,580 patients with chronic lymphocytic leukemia
Next-generation sequencing studies have in recent years revealed numerous recurrently mutated genes in chronic lymphocytic leukemia (CLL). These mutations are usually found in a relatively small percentage of cases and associated ...
Mar 3, 2023
0
91
